(NASDAQ: ERNA) Ernexa Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.89%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 64.64%.
Ernexa Therapeutics's earnings in 2026 is -$12,273,000.On average, 3 Wall Street analysts forecast ERNA's earnings for 2026 to be -$30,004,367, with the lowest ERNA earnings forecast at -$28,827,725, and the highest ERNA earnings forecast at -$30,886,849. On average, 3 Wall Street analysts forecast ERNA's earnings for 2027 to be -$3,097,010, with the lowest ERNA earnings forecast at -$2,975,559, and the highest ERNA earnings forecast at -$3,188,099.
In 2028, ERNA is forecast to generate -$2,114,625 in earnings, with the lowest earnings forecast at -$2,031,699 and the highest earnings forecast at -$2,176,820.